These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 1319303

  • 1. Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
    Jones RN, Erwin ME, Barrett MS.
    Diagn Microbiol Infect Dis; 1992; 15(4):379-81. PubMed ID: 1319303
    [Abstract] [Full Text] [Related]

  • 2. Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
    Jones RN, Johnson DM, Erwin ME.
    Diagn Microbiol Infect Dis; 1994 Feb; 18(2):125-7. PubMed ID: 8062531
    [Abstract] [Full Text] [Related]

  • 3. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
    Erwin ME, Jones RN.
    J Clin Microbiol; 1992 May; 30(5):1170-3. PubMed ID: 1316366
    [Abstract] [Full Text] [Related]

  • 4. Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
    Cormican MG, Jones RN.
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):227-30. PubMed ID: 7554807
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M, Oguri T, Kanno H, Kubo S, Honda M, Satoh K, Daimon Y, Yamanaka K, Sugawara K, Furuta T.
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [Abstract] [Full Text] [Related]

  • 7. Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.
    Barrett MS, Jones RN.
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):462-5. PubMed ID: 1330563
    [Abstract] [Full Text] [Related]

  • 8. Multi-center validation of proposed disk diffusion susceptibility testing interpretive criteria for lomefloxacin using more than 1,500 clinical isolates.
    Cormican MG, Erwin MS, Jones RN.
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):169-72. PubMed ID: 8724404
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Fuchs PC, Barry AL, Pfaller MA.
    J Clin Microbiol; 1993 Aug; 31(8):2236-7. PubMed ID: 8396592
    [Abstract] [Full Text] [Related]

  • 11. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
    Fuchs PC, Barry AL, Jones RN, Thornsberry C, Ayers LW, Gavan TL, Gerlach EH.
    Diagn Microbiol Infect Dis; 1987 Mar; 6(3):185-92. PubMed ID: 3471371
    [Abstract] [Full Text] [Related]

  • 12. In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests.
    Barry AL, Jones RN, Thornsberry C, Ayers LW, Gavan TL, Gerlach EH.
    Eur J Clin Microbiol; 1986 Feb; 5(1):18-22. PubMed ID: 2938944
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Detection of quinolone-resistant Neisseria gonorrhoeae.
    Kam KM, Wong PW, Cheung MM, Ho NK.
    J Clin Microbiol; 1996 Jun; 34(6):1462-4. PubMed ID: 8735098
    [Abstract] [Full Text] [Related]

  • 15. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.
    Sutton LD, Jones RN.
    J Clin Microbiol; 1995 Jan; 33(1):146-8. PubMed ID: 7699031
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
    Jones RN, Barrett MS, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):93-9. PubMed ID: 7805362
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
    Jones RN, Erwin ME, Biedenbach DJ, Johnson DM, Pfaller MA.
    Diagn Microbiol Infect Dis; 1999 Nov; 35(3):227-34. PubMed ID: 10626134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.